Research
Epigenetics Drugs and Diagnostic
Technologies Market is growing at
a CAGR of 19.4 fro! "#1$ to
"#19. %& Transparenc& Market
Research.
Single User License:
USD 4595
Multi User License:
USD 7595
Corporate User License:
USD 10595
Epigenetics Drugs and Diagnostic Technologies Market is
E'pected to Reach ()D *.+ %illion Glo,all& in "#1-.
Transparenc& Market Research
Transparency Market Research
)tate Tower/
9#/ )tate )treet/ )uite +##.
Al,an&/ 01 1""#+
(nited )tates
www.transparenc&!arketresearch.co!
sales2transparenc&!arketresearch.co!
112 Page Report
Publise! Date
2"#$une#201%
&u' (o)
Re*uest Sa+ple
Press Release
Epigenetics Drugs and
Diagnostic Technologies
Market
Epigenetics Drugs and Diagnostic Technologies Market was valued at USD 1.6 billion in 201 and
is esti!ated to reach a !arket worth USD ".# billion in 201$ at a %&'( o) 1$.*+ )ro! 201 to
201$.
&ro)se te ,ull report at ttp:--))).transparenc'+ar/etresearc.co+-epigenetics#
+ar/et.t+l
The growth o) the epigenetics !arket is driven b, )actors such as increase in aging population-
as there is a strong correlation between cancer and aging. &ccording to ./0- it is esti!ated that
global population over the age o) 60 ,ears would double )ro! 11+ 120002 to 22+ 120"02. 3eople
aged 60 and above are !ore prone to cancer. /ence- countries are advocating earl, detection o)
cancer through screening kits 1Epi 3rocolon- Epi 3ro4ung2 which are driving the epigenetic drugs
and diagnostic technologies !arket.
Epigenetic drugs !ake it possible to reverse the aberrant gene e5pression which leads to various
disease states. The inhibitors- D6& !eth,ltrans)erase 1D6MT2 and /istone Deacet,lase 1/D&%2
are responsible )or regulating the cellular e5pression. 0ut o) the two inhibitors- D6MT accounts
)or a larger share as these inhibitors o7er an i!proved access )or targeting the cancerous cells.
%urrentl,- )our drugs are approved b, 8D& and are co!!erciall, available. Two o) the! are
D6MT inhibitors9 %elgene:s ;ida<a 1a<acitidine2 and Eisai:s Dacogen 1decitabine2 )or the
treat!ent o) M,elod,splastic S,ndro!e 1MDS2- and the other two are /D&% inhibitors9 Merck:s
=olin<a 1vorinostat2 and %elgene:s >stoda5 1ro!idepsin2 both )or treat!ent o) %utaneous T %ell
4,!pho!a 1%T%42.
Epigenetics is a rapidl, developing ?eld not onl, in oncolog, but also in non@oncolog, indications
1&l<hei!er:s and arthritis2. Due to the increase in disease identi?cation- !anu)acturers are taking
initiatives in develop!ent o) varied epigenetic diagnostic techniAues. D6& !eth,lation
techniAue in the diagnostic seg!ent accounts )or the largest share as co!pared to histone
!odi?cation techniAues- as the research on D6& !eth,lation has been carried out since
decades- and is thus !ostl, pre)erred. 8urther!ore- with the corresponding advance!ents in
research and technolog,- histone code h,pothesis techniAue ca!e into e5istence onl, in late
Transparenc& Market Research
2
R0P1R2 D0SCR3P231(
Epigenetics Drugs and
Diagnostic Technologies
Market
1$B0s. /ence- with the surge in interest- there is also an increase in invest!ent )or the research
and develop!ent o) histone !odi?cations.
6orth &!erica accounts )or the largest share o) the epigenetics !arket. >t is e5pected that 6orth
&!erica will do!inate around hal) o) the global epigenetics !arket due to increasing incidence
o) cancer and other non@oncolog, indications. 0ncolog, and other non@oncolog, indications
1&l<hei!er:s and arthritis2 are associated with epigeneticsC thus the increasing incidence o)
cancer supports the growth o) the epigenetics !arket. &sia accounts )or nearl, hal) o) the new
cancer cases worldwide. The rising incidence o) cancer cases in the &sian region would boost the
de!and )or epigenetic drugs and diagnostic technologies in this !arket. &ustralia- %hina- Dapan
and South Eorea are the largest !arkets )or these therapies. Dapan do!inates the epigenetics
!arket in &sia@3aci?c due to a signi?cant presence o) co!panies in the therapeutics seg!ent
such as Eisai 3har!aceuticals and 0ncol,s Fiophar!a. These co!panies are taking initiatives )or
the develop!ent and co!!erciali<ation o) epigenetic drugs. ;arious research institutes and
invest!ents )ro! these co!panies would drive the epigenetics !arket.
So!e o) the ke, pla,ers in this !arket include %elgene %orporation- Merck- Eisai
3har!aceuticals- E5act Sciences- Epigeno!ics and others. Manu)acturers are entering into
strategic alliances with nu!erous research institutions and other pla,ers )or the develop!ent
and co!!erciali<ation o) new and innovative drugs- which !ight see new pla,ers in the !arket
looking to carve out a share o) the !arket )or the!selves.
The epigenetics drugs and diagnostic technologies !arket is seg!ented as )ollows9
Epigenetics Drugs Market- b, Mechanis! o) &ction
D6MT >nhibitors
Epigenetics Diagnostic Technologies Market- b, T,pes
D6& Meth,lation
%hro!atin >!!unoprecipitation 1%h>32 Technolog,
Epigenetics Technologies Market- b, 'eograph,
6orth &!erica
Europe
Transparenc& Market Research